Based on the fact that change in the phenotype may mean the possibility to add a precious and potentially life-saving therapeutic option, HER2 reassessment in metastatic lesions should be carefully taken into account, whenever feasible, especially for metastases coming from primary hormone receptor-positive breast cancer (Fabi et al., 2011). Here, ERBB2 is linked to breast cancer.